138 related articles for article (PubMed ID: 34053357)
1. Drug- and patient-related factors are the strongest predictors of endocrine therapy adherence in breast cancer patients.
Haji-Hersi MF; Tilley S; Shelton CA; Lamb N; Kamdem LK
J Oncol Pharm Pract; 2022 Jul; 28(5):1070-1076. PubMed ID: 34053357
[TBL] [Abstract][Full Text] [Related]
2. The relationship between medication adherence and illness perception in breast cancer patients with adjuvant endocrine therapy: beliefs about medicines as mediators.
Zhao M; Zhao J; Chen J; Li M; Zhang L; Luo X; Zhang Y; Xiong C; Guo Z; Yan J
Support Care Cancer; 2022 Dec; 30(12):10009-10017. PubMed ID: 36261611
[TBL] [Abstract][Full Text] [Related]
3. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
4. Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
Pan Y; Heisig SR; von Blanckenburg P; Albert US; Hadji P; Rief W; Nestoriuc Y
Breast Cancer Res Treat; 2018 Apr; 168(3):667-677. PubMed ID: 29330625
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
6. Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews.
Todd A; Waldron C; McGeagh L; Norris R; Bolnykh I; Stewart SJ; Slodkowska-Barabasz J; Moon Z; Cahir C; Thompson S; Harmer V; Wells M; Watson E; Sharp L;
Cancer Med; 2024 Feb; 13(3):e6937. PubMed ID: 38240343
[TBL] [Abstract][Full Text] [Related]
7. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Paranjpe R; John G; Trivedi M; Abughosh S
Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
[TBL] [Abstract][Full Text] [Related]
8. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
9. Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
Doggrell SA
Breast Cancer Res Treat; 2011 Sep; 129(2):299-308. PubMed ID: 21594663
[TBL] [Abstract][Full Text] [Related]
10. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
11. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
12. The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy.
Jiang H; Dong Y; Zong W; Zhang XJ; Xu H; Jin F
BMC Womens Health; 2022 Apr; 22(1):135. PubMed ID: 35477451
[TBL] [Abstract][Full Text] [Related]
13. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
14. The impact of adverse drug reactions on medication adherence and outpatient treatment outcomes in female breast cancer: A review protocol.
Lin ID; Lin KH
J Adv Nurs; 2023 Feb; 79(2):825-831. PubMed ID: 36524324
[TBL] [Abstract][Full Text] [Related]
15. Medication adherence among cardiac patients in Khartoum State, Sudan: a cross-sectional study.
Awad A; Osman N; Altayib S
Cardiovasc J Afr; 2017 Nov/Dec 23; 28(6):350-355. PubMed ID: 28345729
[TBL] [Abstract][Full Text] [Related]
16. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
Pourcelot C; Orillard E; Nallet G; Dirand C; Billion-Rey F; Barbier G; Chouk S; Limat S; Montcuquet P; Henriques J; Paget-Bailly S; Anota A; Chaigneau L; Nerich V
Breast Cancer Res Treat; 2018 May; 169(1):153-162. PubMed ID: 29362956
[TBL] [Abstract][Full Text] [Related]
18. Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
Tan EH; Wong ALA; Tan CC; Wong P; Tan SH; Ang LEY; Lim SE; Chong WQ; Ho J; Lee SC; Tai BC
Breast Cancer Res Treat; 2021 Aug; 188(3):779-788. PubMed ID: 33948777
[TBL] [Abstract][Full Text] [Related]
19. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
